尽管我国持续深化医药卫生体制改革，优化医疗服务价格体系，但群众对医疗费用的"模糊感"仍未 完全消除。部分医疗机构存在检查检验等项目标准不明、院内第三方服务价格游离监管、互联网诊疗公 示滞后、项目动态调整缺乏同步披露等问题，群众往往在"先诊疗、后算账"的不确定中作出被动选择。 《规定》通过明确医疗机构价格公示的方式与标准、义务和责任，为群众提供了"明明白白消费"的制度 依据。这一制度安排与国家深化公立医院改革、推进医疗服务价格分类管理等顶层政策形成合力，推动 医疗服务从"病有所医"稳步迈向"病有良医"。 （三）从"形式公开"到"实质透明"的制度创新 此次公示制度修订实现了从"形式公开"到"实质透明"的系统升级，构建起"立规—监督—执法"的闭 环体系：在范围上，由"核心项目"扩展至"全场所覆盖"，将疫苗接种、医疗救护服务以及医疗机构场所 内的第三方机构一并纳入，打破了医疗机构内的"信息盲区"。在渠道上，从"线下为主"转向"线上线下 融合"，对互联网医院的价格公示提出了详尽、独立的要求，强调了线上线下主体的一致性，兼顾了"数 字普惠"与"传统需求"。在监管上，从"柔性倡导"走向"刚性约束"，明确了"医疗机构未按照本 ...

格隆汇2月3日丨民生健康(301507.SZ)公布，截至2026年1月31日，公司通过回购专用证券账户，以集中 竞价交易方式已累计回购股份1,252,100股，占目前公司总股本的比例为0.35%，最高成交价为15.67元/ 股，最低成交价为14.39元/股，支付金额为18,904,670.00元（不含交易费用）。 ...

证券代码：301507 证券简称：民生健康 公告编号：2026-005 杭州民生健康药业股份有限公司 关于公司控股子公司取得发明专利证书的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 一、取得发明专利的基本情况 近日，杭州民生健康药业股份有限公司（以下简称"公司"）控股子公司民 生中科嘉亿（山东）生物工程有限公司收到国家知识产权局颁发的一项发明专利 证书，具体情况如下： 专利号：ZL 2025 1 0796332.3 专利申请日：2025 年 6 月 16 日 专利权人：民生中科嘉亿（山东）生物工程有限公司 授权公告日：2026 年 1 月 30 日 专利权期限：二十年，自申请日起算 本发明涉及益生菌技术领域，具体涉及维持血糖健康水平的短双歧杆菌 JYBF-220 及其后生元制剂和应用。短双歧杆菌 JYBF-220 制备的后生元制剂可以 预防和改善高血糖，有助于维持血糖在健康水平。本发明专利涉及的菌株尚未应 用于公司或公司控股子公司产品。 二、取得发明专利对公司的影响 上述发明专利的取得不会对公司生产经营产生重大影响，但有利于促进公司 的核心技术 ...

证券代码：301507 证券简称：民生健康 公告编号：2026-006 杭州民生健康药业股份有限公司 关于第二期以集中竞价交易方式回购公司股份的 进展公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 重要内容提示： 第二期回购方案的实施情况：截至 2026 年 1 月 31 日，杭州民生健康药业 股份有限公司（以下简称"公司"）通过回购专用证券账户，以集中竞价交易方式 已累计回购股份 1,252,100 股，占目前公司总股本的比例为 0.35%，最高成交价 为 15.67 元/股，最低成交价为 14.39 元/股，支付金额为 18,904,670.00 元（不含 交易费用）。 一、回购股份的基本情况 公司于 2025 年 10 月 28 日召开第二届董事会第十一次会议，审议通过《关 于第二期以集中竞价交易方式回购公司股份的议案》，同意公司以自有资金通过 集中竞价交易方式实施第二期公司股份回购，用于股权激励。回购价格不超过公 司董事会审议通过回购股份决议前三十个交易日公司股票交易均价的 150%，即 人民币 21.06 元/股；预计回购股份数量为 21 ...

Core Insights - The article highlights the integration of traditional Chinese medicine (TCM) services into the healthcare system of Fushui Town, aiming to meet the health needs of the local population, especially the elderly, while supporting rural revitalization efforts [1] Group 1: Infrastructure Development - The Fushui Town Central Health Center has established itself as a model TCM facility, equipped with various treatment rooms and modern medical equipment to provide comprehensive services [2] - The center has a core team of four experienced TCM physicians and regularly invites local experts to enhance service quality, expanding its offerings to include 18 TCM techniques [2] Group 2: Service Integration - TCM services have been deeply integrated into daily healthcare, with a focus on chronic diseases prevalent among the elderly, achieving a 40% share of TCM in overall medical services since 2025 [3] - A comprehensive service system has been developed, combining in-hospital treatment, community outreach, and online health education to increase accessibility [3] Group 3: Innovative Service Models - The center has introduced a "TCM + Elderly Care" service model, addressing the needs of elderly patients with mobility issues through a dual approach of centralized care and home visits [4][5] - A standardized process for home care services has been established, demonstrating significant improvements in patient recovery and providing a replicable model for similar services in rural areas [5]

"大连银行的多级账簿功能彻底解决了我们多门店资金管理难题，不用烦琐划转资金，就能精准掌握每 家门店的收支情况，对账清晰、监管合规，极大提升了我们服务老年客户的效率。"该医药公司相关负 责人表示，合作以来，企业财务对账效率显著提升，为服务老年群体筑牢了资金管理后盾。 步履不停，持续擦亮金融服务民生底色 未来，大连银行将持续深化养老医疗领域的金融服务创新，将场景化资金管理模式推广至综合医院、社 区医院、养老机构、医药连锁企业等更多服务对象，尤其向县域和乡村地区延伸，打通养老医疗金融服 务"最后一公里"。同时，加强与民政、医保等部门的通力合作，积极探索更多新型服务场景，筑起守护 群众健康养老的"金融安全网"，为增进民生福祉、推进健康中国建设贡献金融力量。 医疗保障与养老服务是关乎千家万户的民生大事，也是金融服务实体经济、践行"金融为民"初心的核心 阵地。大连银行深耕养老医疗领域，以现金管理系统创新为突破口，通过定制化服务模式破解行业资金 管理痛点，在与大连某医药公司的深度合作中，构建起"高效清分、安全透明、场景适配"的金融服务生 态，为守护人民群众健康福祉注入金融动能。 精准破局，定制医药流通资金管理方案 作为区域 ...

发布会现场，中国营养保健食品协会秘书长张中朋深入剖析了中国儿童营养市场从"国际通用"到"中国 定制"；从"通用"到"专属"的发展趋势，肯定了基于中国儿童体质研发的重要价值。中山大学公共卫生 学院营养学系教授蒋卓勤则从专业角度阐述了儿童青少年营养现状，强调了科学分阶段干预的必要性， 维矿营养精准匹配的重要性。 本报讯 （记者冯思婕）1月25日，杭州民生健康药业股份有限公司（以下简称"民生健康"）"百年荣耀· 向未来生长——2026小金维他®品牌战略发布会"在杭州举行。 民生健康控股股东，杭州民生药业股份有限公司（以下简称"民生药业"）董事长竺福江在发布会上表 示，自1926年始创，作为中国最早的四大西药厂之一，民生始终将"提供优质产品，成就他人健康"的使 命铭刻于心。从安嗽露、矽碳银等国民经典，到宝塔糖、21金维他等时代记忆，公司以一个个承载着匠 心与责任的产品，守护了数代中国人的健康。 竺福江特别强调，儿童健康是民族未来的基石。公司有责任、更有能力以百年药企的专业标准，为中国 孩子打造专属的营养品牌。小金维他®品牌的战略发布，正是民生深耕儿童健康赛道、践行社会责任的 坚定宣言。 在坚实的专业基础上，要如何让科 ...

Core Viewpoint - Minsheng Health is committed to enhancing children's health through the launch of its new brand, "Xiao Jin Wei Ta," which aims to provide tailored nutritional solutions for different growth stages, reflecting the company's dedication to social responsibility and professional standards in children's health [1][2]. Group 1: Brand Strategy and Market Positioning - The launch event for "Xiao Jin Wei Ta" emphasized the importance of children's health as a cornerstone for the future of the nation, with the company pledging to create a dedicated nutrition brand for children [1]. - The brand's strategy aligns with the evolving trends in the Chinese children's nutrition market, moving from "international standard" to "China customized" solutions, highlighting the significance of developing products based on Chinese children's physical needs [1][2]. - The collaboration with the globally recognized "Minions" IP aims to enhance brand emotional communication and attract consumer attention, leveraging the character's appeal to both parents and children [2]. Group 2: Strategic Partnerships and Distribution Channels - A strategic partnership with the "Minions" IP is expected to create a dual effect of attracting attention and providing emotional support for children's growth, with the brand planning to capitalize on the release of the new "Minions" movie in 2026 [2]. - The launch of a "Brand Distribution Alliance" signifies a new ecosystem for distribution channels, aiming for collaborative growth with various partners in the market [3]. - The company’s management expressed confidence in the brand's future, emphasizing continuous innovation, strict quality control, and an open partner ecosystem to ensure the health of Chinese children [3].

Core Viewpoint - The research team from Beijing Normal University visited Guangxi Shuangyi Pharmaceutical Co., Ltd. to study the development of ethnic medicine and its industrialization in the context of regional development in ethnic areas [1] Group 1: Company Overview - Guangxi Shuangyi Pharmaceutical is recognized as a national high-tech enterprise and a "specialized, refined, distinctive, and innovative" small and medium-sized enterprise in Guangxi [7] - The company has developed a unique product, the Shuangyi Dampness-Removing Capsule, which is the first recognized Zhuang medicine, utilizing traditional Zhuang medical formulas and modern production techniques [3][8] Group 2: Product Development and Quality - The company emphasizes quality control, with internal standards exceeding national requirements, reflecting its commitment to public health [3] - The annual sales of the compound cold medicine granules exceed 100 million, showcasing the company's successful product line in the Zhuang medicine sector [3] Group 3: Research and Development - The company has established the "Guangxi Zhuang Autonomous Region Medicinal Animal Engineering Research Center," focusing on the research and development of Zhuang and Yao medicines, and holds multiple invention patents [8] - The integration of traditional medicine with modern technology is a key strategy for the company, aiming to modernize ethnic medicine [8] Group 4: Community Engagement and Sustainability - The company employs a "company + cooperative + farmer" model to promote the cultivation of Zhuang and Yao medicinal materials, supporting local communities and ensuring a stable supply of raw materials for production [5] - The establishment of a dedicated medicinal material planting base in the "World Yao Capital" Jinxi Yao Autonomous County enhances the scale and standardization of Zhuang and Yao medicinal resources [5] Group 5: Future Goals - The company aims to continue promoting Zhuang and Yao medical culture, deepen industry-academia-research cooperation, and establish itself as a leader in the production of anti-cold and rheumatism medications in China [10] - The long-term goal is to contribute significantly to the modernization of ethnic regions through the development of the ethnic medicine industry [10]

Core Viewpoint - The strategic partnership between Nanjing University of Science and Technology's School of Materials and the eye health innovation company "Jishu Yandao" aims to leverage advanced materials, specifically rare earth graphene, to address eye health issues and promote the application of original scientific research in the industry [1][3]. Group 1: Collaboration Details - The collaboration is a response to the "Healthy China" strategy, addressing the significant eye health issues faced by the population, with 2.289 billion instances of vision problems reported among China's 1.41 billion people [3]. - The partnership seeks to bridge the gap between basic research, technological breakthroughs, and industrial applications, enhancing the practical impact of new material technologies on public health [3][6]. Group 2: Company Background and Innovations - "Jishu Yandao" has been focused on the graphene eye health sector since 2014, developing functional heating eye masks and has made significant advancements over four product iterations [5]. - The collaboration with Nanjing University of Science and Technology's research team has provided a breakthrough in technology by incorporating rare earth elements into graphene, enhancing thermal penetration depth by 35 times and optimizing the infrared wavelength for better absorption [5][6]. Group 3: Future Directions - The partnership aims to establish a long-term research collaboration mechanism to transform laboratory results into eye health products that benefit the public, thereby improving national eye health standards [8]. - The School of Materials will continue to encourage research teams to align academic studies with societal needs, ensuring that technological innovations serve the public's aspirations for a better life [8].